Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + Axicabtagene Ciloleucel in B-Cell Lymphoma
NCT04257578Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Dec 2020
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in B cell lymphoma, sponsored by University of Washington. Started Dec 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04257578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04257578.